Wendell Gray Yarbrough, MD, MMHC, FACS

Professor of Surgery (Otolaryngology) and of Pathology; Section Chief, Otolaryngology; Co-Director Molecular Virology Research Program; Director, Head & Neck Cancer Program, Smilow Cancer Hospital

Clinical Interests

  • Biopsy
  • Clinical Trials as Topic
  • Head and Neck Neoplasms
  • Laryngeal Neoplasms
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Medical Oncology
  • Mouth Neoplasms
  • Neoplasms
  • Neoplasms, Unknown Primary
  • Otolaryngology
  • Sarcoma
  • Skin Neoplasms
  • General Surgery
  • Thyroid Neoplasms
  • Tracheal Neoplasms
  • Antineoplastic Protocols
  • Early Detection of Cancer
  • Vocal Cord Dysfunction

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Child
Referrals: From patients or physicians

Patient Care Organizations

Surgery: Otolaryngology: Head & Neck Cancer Program

Pathology

Cancer Center: Head & Neck Cancers Program

Yale Medicine

Board Certifications

  • Otolaryngology AB of Otolaryngology (1995)

Clinical Trials

Conditions Study Title
Thyroid A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Lip, Oral Cavity and Pharynx A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
Larynx, Lip, Oral Cavity and Pharynx, Ill-Defined Sites A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Larynx, Lip, Oral Cavity and Pharynx, Thyroid A Phase III Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Lip, Oral Cavity and Pharynx Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Lip, Oral Cavity and Pharynx Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Larynx TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Lip, Oral Cavity and Pharynx Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Lip, Oral Cavity and Pharynx Window Trial 5-aza in HNSCC, T-tare

Edit this profile